News
NeuroOne (Nasdaq:NMTC) announced today that it filed an FDA 510(k) submission for its trigeminal nerve ablation technology.
The following is a summary of “Suicidal Ideation and Self-Injury in Trigeminal Neuralgia,” published in the April 2025 issue ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback